Amgen
3Q Revenues: $5.8 billion (-1%)
3Q Earnings: $2.0 billion (flat)
YTD Revenues: $17.0 billion (flat)
YTD Earnings: $6.2 billion (+8%)
Comments: Enbrel sales were $1.4 billion in the quarter, down 6% due to lower unit demand. Neulasta sales decreased 6% to $1.1 billion due to lower unit demand. Aranesp sales were down 3% to $516 million driven by unfavorable changes in foreign exchange rates and lower unit demand. Prolia sales were $464 million, up 22% driven primarily by higher unit demand. Sensipar/Mimpara sales were up 10% to $457 million driven primarily by net selling price. XGEVA sales decreased 2% to $387 million driven by lower unit demand, offset partially by net selling price. EPOGEN sales were down 21% to $264 million driven primarily by unfavorable changes in net selling price and inventory. KYPROLIS sales were up 13% to $207 million driven by higher unit demand, offset partially by net selling price. Nplate sales increased 5% to $159 million driven by higher unit demand and net selling price. Vectibix sales increased 2% to $168 million driven by higher unit demand. NEUPOGEN sales were down 25% to $138 million, impacted by competition. Repatha sales increased to $89 million driven by higher unit demand. BLINCYTO sales increased 79% to $52 million driven by higher unit demand.